Laetus and STADA agree on partnership for implementation of EU FMD

By February 2019, pharmaceutical companies that manufacture or sell their products in Europe, must have implemented the regulations specified in the EU Falsification Directive (FMD).

This content was submitted directly to this website by the supplier.

This includes the traceability (Track & Trace) of prescription drugs back to the manufacturer. STADA Arzneimittel AG responded to these requirements early on and initiated the appropriate measures. For the implementation of the serialization requirements according to EU-FMD, the manufacturer of generics and OTC brand products relies on Laetus GmbH as its partner. The project covers a total of 30lines at the sites in Germany, Serbia, Montenegro, UK and Russia and involves a good deal of close collaboration.

In choosing Laetus, STADA Arzneimittel AG is placing its trust in a reliable partner with a proven ability to implement serialization projects of this scale and deliver success – backed up by more than forty years‘ experience of in-line quality control and hundreds of successful track & trace installations.

In addition to Secure Track & Trace software (S-TTS), Laetus also offers, among other things, some twenty MV-70-F pack handling systems with integrated weighing and manipulation protection functions (tamper-evident labelling). This machine is particularly suited to integration into existing packaging lines thanks to its compact dimensions.

Further information about the services offered by Laetus:http://www.laetus.com

More in Home